Pharmacoanalytic Core Laboratory

药物分析核心实验室

• 批准号: 7780342
• 负责人: Stan Gee Louie
• 金额: $ 15万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7780342
• 关键词: Animals; Basic Science; Biological Assay; Childhood; Clinical; Clinical Protocols; Collaborations; Comprehensive Cancer Center; Detection; Development; Diagnostic; Drug Kinetics; Environment; Enzyme-Linked Immunosorbent Assay; Fluorescence; Fostering; Human; In Vitro; Laboratories; Lead; Liquid Chromatography; Methods; Mission; Modality; Nucleosides; Nucleotides; Outcome; Pharmaceutical Preparations; Pharmacodynamics; Population; Research Personnel; Resistance; Sampling; Scientist; Techniques; Technology; Testing; Tube; USC/Norris Comprehensive Cancer Center and Hospital; base; design; in vivo Model; meetings; tandem mass spectrometry; tripolyphosphate

The mission of Pharmacoanalytical Laboratory (PAL) is to provide intellectual and analytical support to basic, translational and clinical scientists. For basic science investigators, the PAL assists in the development of discoveries from the "test tube" to potential clinical modalities. Potential anticancer or diagnostic agents derived from laboratory concepts are further developed using in vitro and in vivo models developed with intellectual support from the PAL. For clinicians, the PAL provides analytical and pharmacokinetic/pharmacodynamics support to further understand the underlying mechanisms that may influence clinical outcome. In an effort to meet these needs, the PAL has acquired the capacity to develop specific analytical and biologically-based techniques to support basic, translational and clinically-based efforts. This includes the development of highly sensitive quantification methods by using ELISA- and liquid chromatography tandem mass spectrometry (LC-MS/MS)-based technology. LC-MS/MS-based technology can minimize the amount of sample volume required, thus allowing serial drug analysis in pediatric populations and even in small animals. In addition, the PAL has developed methods using LC-MS/MS to determine intracellular concentration nucleosides and their anabolites that include the activated component, the triphosphate nucleotides. These techniques can also be used to analyze intracellular nucleotide pools to study cellular mechanisms that lead to nucleoside resistance. In addition, the PAL collaborates in the design of clinical protocols having a pharmacokinetic component and evaluates the results of human pharmacokinetic studies. Despite these developments, the PAL has maintained and enhanced its core analytical capacity using HPLC-based assays utilizing UV and fluorescence detection. These assays are reliable analytical capabilities that can support clinical protocols that mandate drug level determinations. The PAL fosters an environment to enhance collaboration between basic, translational and clinical scientists.

药物分析实验室（PAL）的使命是提供智力和分析支持 到基础，翻译和临床科学家。对于基础科学研究者，PAR协助 从“试管”到潜在临床方式的发现的发展。潜在的抗癌或 使用体外和体内模型进一步开发了源自​​实验室概念的诊断剂 在朋友的智力支持下开发。对于临床医生，PAL提供了分析性和 药代动力学/药效学的支持，以进一步了解可能的潜在机制 影响临床结果。 为了满足这些需求，PAN已经获得了开发特定分析的能力 以及基于生物学的技术，以支持基本，转化和临床上的努力。这包括 通过使用ELISA和液相色谱法开发高度敏感的定量方法 串联质谱法（LC-MS/MS）基于技术。基于LC-MS/MS的技术可以将 所需的样品体积量，从而允许小儿种群串行药物分析 小动物。此外，PAL还使用LC-MS/MS开发了方法来确定细胞内 浓度核苷及其代谢物，包括活化成分，三磷酸 核苷酸。这些技术也可以用于分析细胞内核苷酸池以研究细胞 导致核苷耐药性的机制。此外，朋友还合作临床设计 具有药代动力学成分的方案并评估人类药代动力学的结果 研究。 尽管有这些发展，但PAL仍然保持并增强了其核心分析能力 使用基于HPLC的测定法利用紫外线和荧光检测。这些测定是可靠的分析 可以支持授权药物水平确定的临床方案的能力。朋友促进了 增强基本，转化和临床科学家之间协作的环境。